August 14th 2025
Challenging six misconceptions that have characterized product strategies in Central and Eastern European markets.
August 13th 2025
Sources say the President’s focus has shifted.
August 1st 2025
The 15% tariff on pharmaceutical imports from the European Union is not a short term inconvenience, it represents a structural shift in the economics of the US pharmaceutical market.
July 31st 2025
The letter states that the companies have 60 days to meet the President's requirements.
July 1st 2025
Jeff Liter, CEO of Luminary, discusses his company’s approach to CAR-T therapies and why the developing Saudi market has potential.
Hits Like a BRIC
The first wealth is health, wrote American thinker Ralph Waldo Emerson. Indeed, history has taught us (even before Emerson) that health and wealth are inextricably linked-the more money one has, the healthier one is likely to be.
Five-Year Survivor: European Edition
Says Roche UK CEO John Melville: "There is little difference in the incidence of cancer, in broad terms, across Europe, but cancer survival is very different"
Global Report: Single-Source Supply
Stakeholders worry that less competition among drug suppliers in the United Kingdom could mean higher prices and a bigger bill for the National Health Service
Global Report: Ready ... Set ...
The UK has benefited from the stem-cell debate in the US. Several scientists have fled to Europe's more favorable regulatory stance.
Global Report: Please Come Back
A new European collaboration of biotech, pharma, academia, and government takes up the challenge of boosting R&D.
Global Report: A Hope and a Payer
One health insurance company in The Netherlands is offering doctors a financial incentive to prescribe generic statins and proton pump inhibitors. Doctors and patients complained, but a court upheld the practice.
Global Report: The UK's New Code of Conduct
Serious offenders of the new Association of the British Pharmaceutical Industry's Code of Practice can be "named and shamed" with adverts in the trade press. Details of breaches by companies will be posted online.
Global Report: Still Waiting
Traders say parallel distribution of drugs generates savings for patients. Industry says it creates more profits for traders, leaving pharma with less R&D funding.